What is SynerFuse?
SynerFuse operates at the intersection of neuro-orthopedic innovation and chronic pain management. The company has developed an integrated solution for spinal fusion patients, specifically targeting those suffering from chronic low back and leg pain. By utilizing its proprietary Ultra Low Energy (ULE) therapy within the e-TLIF procedure, SynerFuse provides a non-pharmacological alternative to traditional pain management. This approach is particularly critical given the urgent need to reduce reliance on opioid prescriptions for the estimated 90 million Americans affected by chronic back pain. By addressing the root cause of post-surgical discomfort, SynerFuse is carving out a distinct market position as a leader in patient-centric spinal care.
How much funding has SynerFuse raised?
SynerFuse has raised a total of $110K across 1 funding round:
Debt
$110K
Debt (2021): $110K with participation from PPP
Key Investors in SynerFuse
PPP
Public-Private Partnership
What's next for SynerFuse?
With this late-stage capital, SynerFuse is poised to scale its operational footprint and expand the reach of its ULE therapy platform. The strategic focus will likely shift toward broader clinical adoption and the refinement of its commercialization strategy to penetrate the orthopedic market more deeply. As the company transitions from development to widespread implementation, the focus remains on validating the long-term efficacy of its e-TLIF procedure. Investors are closely monitoring the company's ability to disrupt the standard of care in spinal fusion, potentially setting a new benchmark for how medical device firms address the intersection of surgical outcomes and chronic pain management.
See full SynerFuse company page
